Shingles Vaccine Linked to Reduced Dementia Risk

Oxford University study finds Shingrix vaccine delays dementia onset by up to nine months, offering new hope for older adults.

Research shows a 17% lower risk of dementia in those vaccinated with Shingrix compared to Zostavax.
The study observed over 200,000 people aged 65 and older for six years.
Women experienced greater benefits, with a 22% reduction in dementia risk.
Experts call for further research to confirm findings and understand mechanisms.
Shingrix is currently offered to individuals aged 70-79 and those with weakened immune systems.